{
    "xml": "<topic id=\"PHP93593\" outputclass=\"drug\" rev=\"1.17\" type=\"drug\" namespace=\"/drugs/obinutuzumab\" basename=\"obinutuzumab\" title=\"OBINUTUZUMAB\">\n<title>OBINUTUZUMAB</title>\n<body>\r\n<p outputclass=\"interactionsLinks\"> List of individual interactants: <xref format=\"dita\" href=\"#bnf_int_1333\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/obinutuzumab\">Obinutuzumab</xref>\n</p>\n<data name=\"vtmid\">25502511000001105</data>\n<data name=\"classifications\">\n<data name=\"classification\">\n<data name=\"drugClassification\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClassification\" href=\"#_872447286\" title=\"Monoclonal antibodies (antineoplastic)\">Monoclonal antibodies (antineoplastic)</xref>\n</data>\n<data name=\"inheritsFromClass\">\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n</data>\n</data>\n</data>\n<data name=\"primaryDomainOfEffect\">\n<data name=\"domainOfEffect\">  </data>\n</data>\r\n</body>\n<topic id=\"PHP93831\" outputclass=\"indicationsAndDose\" rev=\"1.30\" parent=\"/drugs/obinutuzumab\">\n<title>Indications and dose</title>\n<body>\n<section outputclass=\"indicationAndDoseGroup\">\n<sectiondiv outputclass=\"therapeuticIndications\">\n<p outputclass=\"therapeuticIndication\">Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabine-based therapy is unsuitable due to co-morbidities</p>\n</sectiondiv>\n<p outputclass=\"routesOfAdministration\">By intravenous infusion</p>\n<ul outputclass=\"patientGroups\">\n<li outputclass=\"patientGroup adult\">\n<p>Adult</p>\n<p>(consult product literature or local protocols).</p>\n</li>\n</ul>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93826\" outputclass=\"contraindications\" rev=\"1.11\" parent=\"/drugs/obinutuzumab\">\n<title>Contra-indications</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Contra-indications, further information</title>\n<sectiondiv>\n<p>For onibutuzumab contra-indications, consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93824\" outputclass=\"cautions\" rev=\"1.14\" parent=\"/drugs/obinutuzumab\">\n<title>Cautions</title>\n<body>\n<section outputclass=\"importantAdvice\">\n<title>Cautions, further information</title>\n<sectiondiv>\n<p>For full details on the cautions of obinutuzumab, consult product literature.</p>\n</sectiondiv>\n<sectiondiv>\n<p outputclass=\"title\">Hepatitis B infection and reactivation</p>\n<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>obinutuzumab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93832\" outputclass=\"interactions\" rev=\"1.10\" parent=\"/drugs/obinutuzumab\">\n<title>Interactions</title>\n<body>\n<section outputclass=\"general\">\n<sectiondiv>\n<p>Appendix 1 (obinutuzumab).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93837\" outputclass=\"sideEffects\" rev=\"1.23\" parent=\"/drugs/obinutuzumab\">\n<title>Side-effects</title>\n<body>\n<section outputclass=\"sideEffectsAdvice\">\n<title>Side-effects, further information</title>\n<sectiondiv>\n<p>For full side effect details for obinutuzumab (including monitoring and management), consult product literature.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93825\" outputclass=\"conceptionAndContraception\" parent=\"/drugs/obinutuzumab\">\n<title>Conception and contraception</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Use effective contraception during and for 18 months after treatment.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93833\" outputclass=\"pregnancy\" parent=\"/drugs/obinutuzumab\">\n<title>Pregnancy</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93823\" outputclass=\"breastFeeding\" parent=\"/drugs/obinutuzumab\">\n<title>Breast feeding</title>\n<body>\n<section outputclass=\"generalInformation\">\n<sectiondiv>\n<p>Avoid breast-feeding during and for 18 months after treatment&#8212;present in milk in <i>animal</i> studies.</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93841\" outputclass=\"monitoringRequirements\" parent=\"/drugs/obinutuzumab\">\n<title>Monitoring requirements</title>\n<body>\n<section outputclass=\"monitoringOfPatientParameters\">\n<sectiondiv>\n<p>Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>\n</sectiondiv>\n</section>\n</body>\n</topic>\n<topic id=\"PHP93844\" outputclass=\"nationalFunding\" rev=\"1.16\" parent=\"/drugs/obinutuzumab\">\n<title>National funding/access decisions</title>\n<body>\r\n<section>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisals\">\r\n<p outputclass=\"title\">NICE technology appraisals (TAs)</p>\r\n<sectiondiv outputclass=\"niceTechnologyAppraisal\">\r\n<p outputclass=\"fundingIdentifier\">NICE TA343</p>\r\n<sectiondiv>\r\n<p outputclass=\"title\">Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)</p>\r\n<p>Obinutuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if:</p>\r\n<ul>\r\n<li>bendamustine-based therapy is not suitable <b>and</b>\r\n</li>\r\n<li>the manufacturer provides obinutuzumab with the discount agreed in the patient access scheme.</li>\r\n</ul>\r\n<p>Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p>\n</sectiondiv>\n<xref format=\"html\" href=\"http://www.nice.org.uk/TA343\">www.nice.org.uk/TA343</xref>\n</sectiondiv>\n</sectiondiv>\r\n </section>\r\n\r\n</body>\n</topic>\n<topic id=\"PHP93593-medicinalForms\" outputclass=\"medicinalForms\" parent=\"/drugs/obinutuzumab\">\n<title>Medicinal forms</title>\n<body>\n<section outputclass=\"licensingVariationStatement\">\n<p>There can be variation in the licensing of different medicines containing the same drug.</p>\n</section>\n</body>\n</topic>\n<parents>\n<xref format=\"dita\" scope=\"local\" type=\"drugs\" href=\"#drugs\" title=\"Drugs\" namespace=\"/drugs\">Drugs</xref>\n</parents>\n<children>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101371\" title=\"Solution for infusion\" namespace=\"/drugs/obinutuzumab/solution-for-infusion\">Solution for infusion</xref>\n</children>\n<backlinks>\n<xref format=\"dita\" scope=\"local\" type=\"treatmentSummary\" href=\"#PHP107699\" namespace=\"/about/changes\" title=\"Changes\" count=\"1\" rel=\"backlink\">Changes</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClassifications\" href=\"#PHP106980\" namespace=\"/drug-classifications\" title=\"Drug classifications\" count=\"1\" rel=\"backlink\">Drug classifications</xref>\n</backlinks>\n<links>\n<xref format=\"dita\" scope=\"local\" type=\"interaction\" href=\"#bnf_int_1333\" namespace=\"/interactions/list-of-drug-interactions/cytotoxics/monoclonal-antibodies/obinutuzumab\" title=\"Obinutuzumab\" count=\"1\" rel=\"link\">Obinutuzumab</xref>\n<xref format=\"dita\" scope=\"local\" type=\"drugClass\" href=\"#PHP34582\" namespace=\"/drug-classes/anti-lymphocyte-monoclonal-antibodies\" title=\"ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES\" count=\"1\" rel=\"link\">ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES</xref>\n<xref format=\"dita\" scope=\"local\" type=\"#drugs\" href=\"#drugs\" namespace=\"/drugs\" title=\"Drugs\" count=\"1\" rel=\"link\">Drugs</xref>\n<xref format=\"dita\" scope=\"local\" type=\"medicinalForm\" href=\"#PHP101371\" namespace=\"/drugs/obinutuzumab/solution-for-infusion\" title=\"Solution for infusion\" count=\"1\" rel=\"link\">Solution for infusion</xref>\n</links>\n</topic>",
    "id": "PHP93593",
    "outputclass": "drug",
    "rev": "1.17",
    "type": "drug",
    "namespace": "/drugs/obinutuzumab",
    "basename": "obinutuzumab",
    "title": "OBINUTUZUMAB",
    "interactants": [
        {
            "id": "bnf_int_1333",
            "label": "Obinutuzumab"
        }
    ],
    "vtmid": "25502511000001105",
    "drugClassification": [
        "Monoclonal antibodies (antineoplastic)"
    ],
    "inheritsFromClass": [
        "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES"
    ],
    "primaryDomainOfEffect": {
        "": {
            "domain": "",
            "therapeuticUses": {}
        }
    },
    "indicationsAndDoses": {
        "indicationAndDoseGroups": [
            {
                "indications": [
                    {
                        "textContent": "Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabine-based therapy is unsuitable due to co-morbidities",
                        "html": "Treatment of previously untreated chronic lymphocytic leukaemia in patients for whom full-dose fludarabine-based therapy is unsuitable due to co-morbidities"
                    }
                ],
                "specificity": {
                    "routes": [
                        "intravenous infusion"
                    ],
                    "textContent": "By intravenous infusion",
                    "html": "By intravenous infusion"
                },
                "adult": [
                    {
                        "textContent": "(consult product literature or local protocols).",
                        "html": "<p>(consult product literature or local protocols).</p>"
                    }
                ]
            }
        ]
    },
    "contraindications": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For onibutuzumab contra-indications, consult product literature.",
                "html": "<p>For onibutuzumab contra-indications, consult product literature.</p>"
            }
        ]
    },
    "cautions": {
        "importantAdvice": [
            {
                "type": "importantAdvice",
                "textContent": "For full details on the cautions of obinutuzumab, consult product literature.",
                "html": "<p>For full details on the cautions of obinutuzumab, consult product literature.</p>"
            },
            {
                "type": "importantAdvice",
                "title": "Hepatitis B infection and reactivation",
                "textContent": "Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking obinutuzumab. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).",
                "html": "<p>Hepatitis B infection and reactivation (including fatal cases) have been reported in patients taking <b>obinutuzumab</b>. Patients with positive hepatitis B serology should be referred to a liver specialist for monitoring and initiation of antiviral therapy before treatment initiation; treatment should not be initiated in patients with evidence of current hepatitis B infection until the infection has been adequately treated. Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>"
            }
        ]
    },
    "interactions": {
        "general": [
            {
                "type": "general",
                "textContent": "Appendix 1 (obinutuzumab).",
                "html": "<p>Appendix 1 (obinutuzumab).</p>"
            }
        ]
    },
    "sideEffects": {
        "advice": [
            {
                "type": "advice",
                "textContent": "For full side effect details for obinutuzumab (including monitoring and management), consult product literature.",
                "html": "<p>For full side effect details for obinutuzumab (including monitoring and management), consult product literature.</p>"
            }
        ]
    },
    "conceptionAndContraception": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Use effective contraception during and for 18 months after treatment.",
                "html": "<p>Use effective contraception during and for 18 months after treatment.</p>"
            }
        ]
    },
    "pregnancy": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.",
                "html": "<p>Avoid unless potential benefit outweighs risk of B-lymphocyte depletion in fetus.</p>"
            }
        ]
    },
    "breastFeeding": {
        "generalInformation": [
            {
                "type": "generalInformation",
                "textContent": "Avoid breast-feeding during and for 18 months after treatment&#8212;present in milk in animal studies.",
                "html": "<p>Avoid breast-feeding during and for 18 months after treatment&#8212;present in milk in <i>animal</i> studies.</p>"
            }
        ]
    },
    "monitoringRequirements": {
        "patientParameters": [
            {
                "type": "patientParameters",
                "textContent": "Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).",
                "html": "<p>Patients should be closely monitored for clinical and laboratory signs of active hepatitis B infection during treatment and for up to a year following the last infusion (consult product literature).</p>"
            }
        ]
    },
    "nationalFunding": {
        "niceTechnologyAppraisals": [
            {
                "type": "niceTechnologyAppraisals",
                "references": [
                    {
                        "id": "http://www.nice.org.uk/TA343",
                        "label": "www.nice.org.uk/TA343"
                    }
                ],
                "fundingIdentifier": "NICE TA343",
                "textContent": "Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015) Obinutuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if: bendamustine-based therapy is not suitable and the manufacturer provides obinutuzumab with the discount agreed in the patient access scheme. Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.\n\nwww.nice.org.uk/TA343",
                "html": "<p outputclass=\"title\">Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (June 2015)</p> <p>Obinutuzumab, in combination with chlorambucil, is an option for untreated chronic lymphocytic leukaemia in patients who have comorbidities that make full-dose fludarabine-based therapy unsuitable for them, only if:</p> <ul> <li>bendamustine-based therapy is not suitable <b>and</b> </li> <li>the manufacturer provides obinutuzumab with the discount agreed in the patient access scheme.</li> </ul> <p>Patients currently receiving obinutuzumab that is not recommended according to the above criteria should have the option to continue treatment until they and their clinician consider it appropriate to stop.</p><xref format=\"html\" href=\"http://www.nice.org.uk/TA343\">www.nice.org.uk/TA343</xref>"
            }
        ]
    },
    "medicinalForms": {
        "licensingVariationStatement": [
            {
                "type": "licensingVariationStatement",
                "textContent": "There can be variation in the licensing of different medicines containing the same drug.",
                "html": "<p>There can be variation in the licensing of different medicines containing the same drug.</p>"
            }
        ]
    },
    "children": {
        "medicinalForm": [
            {
                "id": "PHP101371",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    },
    "backlinks": {
        "treatmentSummary": [
            {
                "id": "PHP107699",
                "label": "Changes",
                "type": "treatmentSummary"
            }
        ],
        "drugClassifications": [
            {
                "id": "PHP106980",
                "label": "Drug classifications",
                "type": "drugClassifications"
            }
        ]
    },
    "links": {
        "interaction": [
            {
                "id": "bnf_int_1333",
                "label": "Obinutuzumab",
                "type": "interaction"
            }
        ],
        "drugClass": [
            {
                "id": "PHP34582",
                "label": "ANTI-LYMPHOCYTE MONOCLONAL ANTIBODIES",
                "type": "drugClass"
            }
        ],
        "#drugs": [
            {
                "id": "drugs",
                "label": "Drugs",
                "type": "#drugs"
            }
        ],
        "medicinalForm": [
            {
                "id": "PHP101371",
                "label": "Solution for infusion",
                "type": "medicinalForm"
            }
        ]
    }
}